Skip to content

TEVA PHARMACEUTICAL INDUSTRIES LIMITED: basic earnings per share

Basic earnings per share for TEVA PHARMACEUTICAL INDUSTRIES LIMITED. Inspect selected reporting periods, original units and SEC filing links; download the financial history.

All TEVA PHARMACEUTICAL INDUSTRIES LIMITED financial histories

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2007-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.

Selected filing history

Basic earnings per share in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
2025-01-012025-12-311.23USD/shares2026-02-0310-K · 0001193125-26-034532
2024-01-012024-12-31-1.45USD/shares2026-02-0310-K · 0001193125-26-034532
2023-01-012023-12-31-0.5USD/shares2026-02-0310-K · 0001193125-26-034532
2022-01-012022-12-31-2.2USD/shares2025-02-0510-K · 0001193125-25-020826
2021-01-012021-12-310.38USD/shares2024-02-1210-K · 0001193125-24-031005
2020-01-012020-12-31-3.64USD/shares2023-02-1010-K · 0001193125-23-031250
2019-01-012019-12-31-0.91USD/shares2022-02-0910-K · 0001193125-22-032667
2018-01-012018-12-31-2.35USD/shares2021-02-1010-K · 0001193125-21-036239
2017-01-012017-12-31-16.26USD/shares2020-02-2110-K · 0001193125-20-044221
2016-01-072016-12-310.07USD/shares2019-02-1910-K · 0001193125-19-043564
2016-01-012016-12-310.07USD/shares2018-02-1210-K · 0001193125-18-039076
2015-01-012015-12-311.84USD/shares2018-02-1210-K · 0001193125-18-039076
2014-01-012014-12-313.58USD/shares2017-02-1520-F · 0001193125-17-045463
2013-01-012013-12-311.49USD/shares2016-02-1120-F · 0001193125-16-459785
2012-01-012012-12-312.25USD/shares2015-02-0920-F · 0001193125-15-039151
2011-01-012011-12-313.1USD/shares2014-02-1020-F · 0001193125-14-041871
2010-01-012010-12-313.72USD/shares2013-02-1220-F · 0001193125-13-050510
2009-01-012009-12-312.29USD/shares2012-02-1720-F · 0001193125-12-067417
2008-01-012008-12-310.78USD/shares2011-02-1520-F · 0001193125-11-036753
2007-01-012007-12-312.49USD/shares2010-02-2220-F · 0001193125-10-036435

Related financial histories

Inspect the source

Entity
TEVA PHARMACEUTICAL INDUSTRIES LIMITED / CIK 0000818686
Captured
2026-09-19T15:07:07.385Z
SEC response SHA-256
f2c93c1e5a25cb18cb0b293c07294b344882e3789d9edd47f98fdd8c904c6c6d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000818686.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))